. Author manuscript; available in PMC: 2023 Dec 1.

Published in final edited form as: J Pediatr Urol. 2022 Jun 20;18(6):848–855. doi: 10.1016/j.jpurol.2022.06.004

Supplemental Table A.1.

Antibiotic Resistance Patterns

	Total (N = 137)	<2-Months-Old (N = 59)	2–24-Months-Old (N = 78)	P-Value
Ampicillin	66 (48.2%)	29 (49.2%)	37 (47.4%)	0.979
Other^a	43 (31.4%)	17 (28.8%)	26 (33.3%)	0.705
Ampicillin/Sulbactam	41 (29.9%)	18 (30.5%)	23 (29.5%)	1.000
Ancef	35 (25.5%)	13 (22.0%)	22 (28.2%)	0.534
Bactrim	32 (23.3%)	16 (27.1%)	16 (20.5%)	0.483
Ceftriaxone^b	8 (5.8%)	5 (8.5%)	3 (3.8%)	0.289
Cipro^b	8 (5.8%)	3 (5.1%)	5 (6.4%)	1.000
Gentamicin^b	7 (5.1%)	2 (3.4%)	5 (6.4%)	0.699
Not Available	11 (8.0%)	3 (5.1%)	8 (10.3%)	0.350

Amoxicillin/K Clavanate (N = 10), Tobramycin (N = 9), Aztreonam (N = 9), Cefuroxime (N = 9), Ceftazidime (N = 8), Cefotaxime (N = 7), Cefepime (N = 7), Cephalothin (N = 7), Cefuroxime (Oral) (N = 6), Levofloxacin (N = 5), Cefoxitin (N = 6), Cefuroxime (Parenteral) (N = 3), Tetracycline (N = 3), Nitrofurantoin (N=3), Amoxicillin (N=3), Gentamicin (N = 2), Penicillin (N = 1), Rifampin (N = 1), Penicillin G (N = 1), Keflex (N=1), Tazo (N=1), Vancomycin (N=1), Amikacin (N=0), Omnicef (N=0), Cefixime (N=0), Clindamycin (N=0), Fluconazole (N=0).

Fisher Exact Test